Table 1.
The main characteristics of the studies with survival outcomes used in the meta-analysis
| Author | Published year | Country | Trial method | Study term | Inclusion criteria | Exclusion criteria | Study endpoint | Total number cases (n) | Pathological review for DCIS-Mi |
|---|---|---|---|---|---|---|---|---|---|
| Fang Y, et al | 2016 | China | Retrospective study | 2002–2014 | DCIS, DCIS-Mi, or DCIS-T1a | NA | NA |
DCIS: 359, DCIS-Mi: 84 (DCIS-T1a: 159) |
NA |
| Wang L, et al | 2015 | China | Retrospective study | 2002–2009 | DCIS or DCIS-Mi | NA | NA | DCIS: 451, DCIS-Mi: 131 | All patients who were diagnosed as DCIS-Mi, were confirmed by two of the authors |
| Yu KD, et al | 2011 | China | Retrospective study | 1998–2007 | Female, primary breast cancer without distant metastases, diagnosis of breast carcinoma in situ (pure DCIS, DCIS-Mi or DCIS with invasion) | NA | NA |
DCIS: 271, DCIS-Mi: 67, DCIS-invasive component: 212 |
The pathologic and IHC outcomes were originally checked and approved by two pathologists |
| Parikh RP, et al | 2012 | USA | Retrospective study | 1973–2004 | DCIS or DCIS-Mi | NA | LRFS, DMFS, OS | DCIS: 321, DCIS-Mi: 72 | NA |
| Pu T, et al | 2018 | China*1 | Retrospective study | 1997–2014 | DCIS or DCIS-Mi or IDC (T1) | NA | Primary: DFS, Secondary: BCSS*2 | DCIS: 280, DCIS-Mi: 242, IDC (T1): 347 | All diagnoses were confirmed by two pathologists |
| Kim M, et al | 2018 | Korea | Retrospective study | 2003–2014 | DCIS or DCIS-Mi | NA | NA | DCIS: 477, DCIS-Mi: 136 | All cases were reviewed by two pathologists |
| Sue G, et al | 2013 | USA | Retrospective study | 2000–2003 | DCIS or DCIS-Mi | Invasive carcinoma which is greater than 1 mm | Loco-regional recurrence and/or distant metastasis, OS | DCIS:154, DCIS-Mi: 51 | All cases were reviewed by a board-certified pathologist at their institution |
| Bertozzi S, et al | 2019 | Italy | Retrospective study | 2002–2016 | DCIS or IDC (sized ≤ 2 cm) | All histotypes other than ductal carcinoma, male breast cancer, and tumors sized > 2 cm | NA | DCIS: 543, DCIS-Mi: 84, IDC (T1): 2111 | NA |
| Mamtani A, et al | 2019 | USA*1 | Retrospective study | 1995–2015 | DCIS or DCIS-Mi | NA | LRR | DCIS: 2700, DCIS-Mi: 421 | NA |
| Zheng J, et al | 2020 | China | Retrospective study | 2014–2018 | DCIS or DCIS-Mi or IDC (T1) | NA | NA | DCIS: 308, DCIS-Mi: 92, IDC (T1a/b/c): 1486 | All cases were reviewed by two senior pathologists |
BCSS breast cancer specific survival, DCIS ductal carcinoma in situ, DCIS-Mi ductal carcinoma in situ with microinvasion, DFS disease-free survival, DMFS distant metastasis-free survival, IDC invasive ductal carcinoma, IHC immunohistochemical, LRFS loco-regional recurrence-free survival, LRR loco-regional recurrence, NA not available, OS overall survival
*1Multi-institutions
*2BCSS: The time from the date of diagnosis to death of breast cancer